PMN – promis neurosciences inc. - common shares (US:NASDAQ)
Stock Stats
News
Promis Neurosciences (NASDAQ:PMN) had its price target lowered by analysts at Guggenheim from $125.00 to $35.00. They now have a "buy" rating on the stock.
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 [Canadian Business Journal (Canada)]
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
Form SCHEDULE 13G ProMIS Neurosciences Filed by: Deep Track Capital, LP
Form 4 ProMIS Neurosciences For: Feb 03 Filed by: Cashman Neil
Form 4 ProMIS Neurosciences For: Feb 03 Filed by: Kaplan Johanne
Form 4 ProMIS Neurosciences For: Feb 03 Filed by: Warma Neil K
Form 4 ProMIS Neurosciences For: Feb 03 Filed by: Milbury Max A.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.